KR960700742A - 아토피성질환 치료약(atopic disease remedy) - Google Patents

아토피성질환 치료약(atopic disease remedy) Download PDF

Info

Publication number
KR960700742A
KR960700742A KR1019950704026A KR19950704026A KR960700742A KR 960700742 A KR960700742 A KR 960700742A KR 1019950704026 A KR1019950704026 A KR 1019950704026A KR 19950704026 A KR19950704026 A KR 19950704026A KR 960700742 A KR960700742 A KR 960700742A
Authority
KR
South Korea
Prior art keywords
atopic
drug
interferon
atopic disease
atopic diseases
Prior art date
Application number
KR1019950704026A
Other languages
English (en)
Other versions
KR100278351B1 (ko
Inventor
시로오 이이노
요시하루 카와시마
Original Assignee
마에다 카쯔노수케
토오레 카부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 마에다 카쯔노수케, 토오레 카부시키가이샤 filed Critical 마에다 카쯔노수케
Publication of KR960700742A publication Critical patent/KR960700742A/ko
Application granted granted Critical
Publication of KR100278351B1 publication Critical patent/KR100278351B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Birds (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

인터페론 β를 유효성분으로 하는 아토피성질환 치료약이다. 본 발명의 치료약은, 아토피성 피부염의 피부증상을 유의하게 개선하고, 알레르기반응의 산생요인인 혈중 호산구수를 분명하게 감소시키며, 또한 효과가 빠르고 지속성이 있으므로, 아토피성질환 치료약으로서 유용하다.

Description

아토피성질환 치료약(ATOPIC DISEASE REMEDY)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (4)

  1. 인터페론 β를 유효성분으로 하는 아토피성질환 치료약.
  2. 제1항에 있어서, 인터페론 β가 천연형인 아토피성질환 치료약
  3. 제1항에 있어서, 인터페론 β 및 약리학적으로 허용되는 담체를 혼합한 의약조성물로 이루어지는 아토피성 질환 치료약
  4. 제1항에 있어서, 아토피성질환이 아토피성 피부염 또는 아토피성 천식인 아토피성질환 치료약
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950704026A 1994-01-28 1994-01-28 아토피성질환 치료약 KR100278351B1 (ko)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP1994/000124 WO1995020395A1 (fr) 1994-01-28 1994-01-28 Medicament contre des maladies atopiques

Publications (2)

Publication Number Publication Date
KR960700742A true KR960700742A (ko) 1996-02-24
KR100278351B1 KR100278351B1 (ko) 2001-01-15

Family

ID=14098153

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950704026A KR100278351B1 (ko) 1994-01-28 1994-01-28 아토피성질환 치료약

Country Status (6)

Country Link
US (1) US5709853A (ko)
EP (1) EP0694307B1 (ko)
JP (1) JP3269125B2 (ko)
KR (1) KR100278351B1 (ko)
DE (1) DE69427970T2 (ko)
WO (1) WO1995020395A1 (ko)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69434777T2 (de) * 1993-07-27 2007-06-14 Mario Bigazzi Verwendung von Relaxin zur Herstellung von therapeutischer Mittel
JP3269125B2 (ja) * 1994-01-28 2002-03-25 東レ株式会社 アトピー性皮膚炎治療薬
US6121247A (en) * 1996-03-29 2000-09-19 The Johns Hopkins University Therapy for allergic diseases
JP3845915B2 (ja) * 1996-10-31 2006-11-15 東レ株式会社 ネコのアトピー性皮膚炎治療剤および治療方法
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US6610713B2 (en) * 2000-05-23 2003-08-26 North Shore - Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
WO2003072135A2 (en) * 2002-02-26 2003-09-04 North Shore-Long Island Jewish Research Insitute Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors
US20160250097A9 (en) * 2004-03-25 2016-09-01 The Feinstein Institute For Medical Research Treatment of inflammation by non-invasive stimulation
CA2560756A1 (en) * 2004-03-25 2005-10-06 The Feinstein Institute For Medical Research Methods and devices for reducing bleed time using vagus nerve stimulation
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
WO2006073484A2 (en) 2004-12-27 2006-07-13 North Shore-Long Island Jewish Research Institute Treating inflammatory disorders by electrical vagus nerve stimulation
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
CA3000408C (en) 2007-01-29 2024-04-02 Lungpacer Medical Inc. Transvascular nerve stimulation apparatus and methods
WO2009029614A1 (en) 2007-08-27 2009-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
US9211409B2 (en) * 2008-03-31 2015-12-15 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of T-cell activity
US20090275997A1 (en) * 2008-05-01 2009-11-05 Michael Allen Faltys Vagus nerve stimulation electrodes and methods of use
EP2355893B1 (en) * 2008-11-18 2013-12-25 Setpoint Medical Corporation Devices for optimizing electrode placement for anti-inflamatory stimulation
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
AU2010258792B2 (en) * 2009-06-09 2015-07-02 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US11051744B2 (en) 2009-11-17 2021-07-06 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
CN102821814B (zh) 2009-12-23 2015-07-15 赛博恩特医疗器械公司 用于治疗慢性炎症的神经刺激设备和系统
WO2012154865A2 (en) 2011-05-09 2012-11-15 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
DE102011052816A1 (de) * 2011-08-18 2013-02-21 Tigo Gmbh Verwendung von Interferon-beta zur Behandlung von Alopecia areata
EP2822645B1 (en) 2012-03-05 2017-05-03 Simon Fraser University Transvascular nerve stimulation apparatus
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
EP2863987B1 (en) 2013-06-21 2023-08-02 Lungpacer Medical Inc. Transvascular diaphragm pacing systems
JP6456382B2 (ja) 2013-11-22 2019-01-23 ラングペーサー メディカル インコーポレイテッドＬｕｎｇｐａｃｅｒ Ｍｅｄｉｃａｌ Ｉｎｃ． カテーテル
EP3824949B1 (en) 2014-01-21 2023-12-20 Lungpacer Medical Inc. Systems for optimization of multi-electrode nerve pacing
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
WO2016126807A1 (en) 2015-02-03 2016-08-11 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
CN114904142A (zh) 2016-01-20 2022-08-16 赛博恩特医疗器械公司 迷走神经刺激的控制
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
US10314501B2 (en) 2016-01-20 2019-06-11 Setpoint Medical Corporation Implantable microstimulators and inductive charging systems
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
US10293164B2 (en) 2017-05-26 2019-05-21 Lungpacer Medical Inc. Apparatus and methods for assisted breathing by transvascular nerve stimulation
JP7184370B2 (ja) 2017-06-30 2022-12-06 ラングペーサー メディカル インコーポレイテッド 認知障害の予防、緩和、及び／または治療のための装置
US10195429B1 (en) 2017-08-02 2019-02-05 Lungpacer Medical Inc. Systems and methods for intravascular catheter positioning and/or nerve stimulation
US10940308B2 (en) 2017-08-04 2021-03-09 Lungpacer Medical Inc. Systems and methods for trans-esophageal sympathetic ganglion recruitment
US11173307B2 (en) 2017-08-14 2021-11-16 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
US20190175908A1 (en) 2017-12-11 2019-06-13 Lungpacer Medical Inc. Systems and methods for strengthening a respiratory muscle
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
WO2020097331A1 (en) 2018-11-08 2020-05-14 Lungpacer Medical Inc. Stimulation systems and related user interfaces
WO2020232333A1 (en) 2019-05-16 2020-11-19 Lungpacer Medical Inc. Systems and methods for sensing and stimulation
EP3983057A4 (en) 2019-06-12 2023-07-12 Lungpacer Medical Inc. CIRCUIT FOR MEDICAL STIMULATION SYSTEMS
EP4153053A4 (en) 2020-05-21 2024-06-19 The Feinstein Institutes for Medical Research SYSTEMS AND METHODS FOR VAGUS NERVE STIMULATION

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8522336D0 (en) * 1985-09-09 1985-10-16 Biogen Nv Composition for treatment of allergies
ES2071977T3 (es) * 1989-12-01 1995-07-01 Childrens Medical Center Uso de interferon gamma para la fabricacion de un medicamento en el tratamiento del asma dependiente de esteroides.
JP3269125B2 (ja) * 1994-01-28 2002-03-25 東レ株式会社 アトピー性皮膚炎治療薬

Also Published As

Publication number Publication date
DE69427970D1 (de) 2001-09-20
US5709853A (en) 1998-01-20
KR100278351B1 (ko) 2001-01-15
DE69427970T2 (de) 2001-11-29
WO1995020395A1 (fr) 1995-08-03
EP0694307B1 (en) 2001-08-16
EP0694307A1 (en) 1996-01-31
EP0694307A4 (en) 1996-05-08
JPH0648957A (ja) 1994-02-22
JP3269125B2 (ja) 2002-03-25

Similar Documents

Publication Publication Date Title
KR960700742A (ko) 아토피성질환 치료약(atopic disease remedy)
ATE241365T1 (de) Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen
KR920019342A (ko) 골질환 치료제
PT1040830E (pt) Medicamento para doencas neurodegenerativas
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
BR9712523A (pt) Novos derivados de pirazol heterociclilmetil-substituìdos
KR950700060A (ko) 운동 뉴우런 질병의 치료에 유용한 약품을 얻기 위한 2-아미노-6-트리플루오로메톡시 벤조티아졸(리루졸)의 사용(Application of 2-amino 6-trifluoromethoxy benzothiazole(riluzole) for obtaining a drug useful in the treatment of motor neuron diseases)
KR950031060A (ko) 골다공증 치료용 약제학적 조성물
FR2711140B1 (fr) 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant.
DK0945136T3 (da) Topisk lægemiddel indeholdende ciclosporin
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
KR950031063A (ko) 프라바스타틴을 이용하여 관상 동맥 아테롬성 동맥경화증의 진행 속도를 감소시키는 방법
ATE235901T1 (de) Pharmazeutische zusammensetzung enthaltend 3-(2,2,2-trimethylhydrazinium)proprionat und gamma- butyrobetain für die behandlung von herz-gefäss- erkrankungen
FR2713640B1 (fr) Nouveaux composés aromatiques polycycliques, compositions pharmaceutiques et cosmétiques les contenant et utilisations.
DK1343472T3 (da) Thixotropisk næsespray
KR930019224A (ko) 유산 위험 치료제
ATE220922T1 (de) Konjugat aus einem wirkstoff, einem polyether und ggf. einem nicht als körperfremd angesehenen, nativen protein
BR0115881A (pt) Emprego de compostos ciclohexanona substituìdos de 6-dimetilaminometil-1-fenil para a terapia da incontinência urinária
ATE331523T1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
ATE293445T1 (de) Herstellung reiner stereoisomere von tricyclo- (5.2.1.0(2.6) )-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel
KR960003718A (ko) 말초신경병 및 중추신경변성병의 치료에 유용한 의약의 제조를 위한 이펜프로딜 및 그 부분입체이성질체의 이용
BR0311180A (pt) Métodos para o tratamento de doenças e condições respiratórias utilizando um inibidor seletivo da inos
ATE258229T1 (de) Substanz fa-70d, herstellungsverfahren und verwendungen
ES2144857T3 (es) Utilizacion de derivados benzonaftalenicos para la fabricacion de medicamentos destinados para el tratamiento de las enfermedades del sistema nervioso.
ES2162040T3 (es) Utilizacion de un conjugado de un agente citostatico y albumina para producir medicamentos antiinflamatorios.

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee